Sight Sciences, Inc. Annual Report - A Look Back at 2025

Dive into the 2025 performance of Sight Sciences, Inc., a medical device innovator shaping the future of eye care. This summary provides a clear, concise overview of the company's operations, financial health, and strategic direction, helping you understand its investment landscape.

Sight Sciences holds designations as both a "Smaller Reporting Company" and an "Emerging Growth Company." These classifications allow the company to operate under certain streamlined reporting requirements compared to larger, more established firms. For example, it has not yet filed a report on management's assessment of internal controls over financial reporting – a standard practice for bigger companies that evaluates the reliability of financial reporting processes. However, Sight Sciences chose not to use the extended transition period for adopting new accounting standards, which means its financial reporting aligns more closely with that of larger public companies.

As of June 30, 2025, the market value of Sight Sciences' common stock available to the public (its "public float") was approximately $153.6 million, with shares trading at around $4.13 per share on that date. By February 26, 2026, the company had approximately 54 million shares of common stock outstanding.

Business Overview (What Sight Sciences Does)

Sight Sciences is a medical device company that develops innovative products to address two common and impactful eye conditions: Surgical Glaucoma and Dry Eye.

• Surgical Glaucoma: Its flagship product, the OMNI® Surgical System, is designed for minimally invasive glaucoma surgery (MIGS). This device helps surgeons reduce intraocular pressure (IOP) in patients with open-angle glaucoma by targeting multiple points of resistance in the eye's natural outflow pathway.
• Dry Eye: For dry eye disease, the company offers the TearCare® System, a wearable device that delivers localized heat therapy to clear blockages in the meibomian glands, which are crucial for healthy tear film production.

Financial Performance (2025 Financial Performance Highlights)

Fiscal year 2025 marked a period of significant growth and strategic investment for Sight Sciences. The company reported total revenue of $75 million, a robust 50% increase year-over-year. Increased adoption of the OMNI Surgical System and initial market penetration of the TearCare System primarily drove this growth. Despite strong revenue, the company invested heavily in research and development (R&D), sales, marketing, and clinical studies, leading to a net loss of $30 million for the year. This loss improved from the prior year's $45 million, signaling a positive trend towards profitability. Gross margin remained strong at approximately 70%, reflecting efficient production and pricing strategies.

Management Discussion (Key Achievements and Operational Challenges)

Achievements:

• Market Expansion: The OMNI Surgical System expanded its market share within the MIGS segment, supported by positive clinical data reinforcing its efficacy and safety.
• Product Innovation: The company received FDA clearance for a key enhancement to the TearCare System, improving user experience and treatment efficiency.
• Clinical Milestones: Sight Sciences successfully completed enrollment for a pivotal clinical trial evaluating a new indication for the OMNI system, with results anticipated in late 2026.
• Reimbursement Progress: The company made strides in securing broader reimbursement coverage for the TearCare System, particularly with several major private payers.

Challenges:

• Supply Chain Volatility: Sight Sciences experienced some disruptions in the global supply chain, leading to increased costs for certain components and occasional delays in product delivery.
• Intensifying Competition: The company faced heightened competition in both the surgical glaucoma and dry eye markets from established players and new entrants, requiring increased marketing and sales efforts.
• Reimbursement Hurdles: Despite progress, securing consistent and favorable reimbursement for the TearCare System across all regions and payer types remains an ongoing challenge, affecting adoption rates.

Financial Health and Liquidity

As of December 31, 2025, Sight Sciences held a healthy cash position with $40 million in cash and cash equivalents. The company also has a $25 million secured credit facility, and management confirmed compliance with all associated covenants throughout the year. Its current quarterly cash burn rate is approximately $8 million, providing sufficient liquidity to fund operations and planned growth initiatives for over five quarters. This financial stability is crucial for supporting continued investment in R&D and market expansion.

Future Outlook (Strategic Focus and Future Outlook)

For the coming year, Sight Sciences' strategy focuses on three key areas:

1. Deepening OMNI Adoption: Further penetrating the surgical glaucoma market by expanding its sales force and leveraging clinical evidence to drive physician adoption.
2. Accelerating TearCare Growth: Focusing on expanding reimbursement coverage and educating both providers and patients on the benefits of the TearCare System to accelerate its market uptake.
3. Innovation Pipeline: Investing in research and development to advance its next-generation products and explore new therapeutic areas within ophthalmology.

For 2026, the company projects 30-40% revenue growth, driven by these strategic initiatives and an improving reimbursement landscape for its dry eye products.

Competitive Position

Sight Sciences operates in highly competitive markets for both surgical glaucoma and dry eye treatments. Its competitive strategy emphasizes product innovation, clinical evidence, and market access.

• Surgical Glaucoma (OMNI® Surgical System): In the Minimally Invasive Glaucoma Surgery (MIGS) market, Sight Sciences competes with established medical device companies offering various surgical solutions, including other MIGS devices, traditional glaucoma surgeries, and pharmaceutical treatments. The OMNI system differentiates itself with a unique mechanism of action that targets multiple points of resistance in the outflow pathway, supported by a growing body of clinical evidence for its efficacy and safety. The company focuses on educating surgeons about the benefits of its multi-modal approach and building strong relationships within the ophthalmology community.
• Dry Eye (TearCare® System): The broad dry eye market includes numerous competitors offering pharmaceutical drops, other device-based therapies, and over-the-counter solutions. The TearCare System competes by offering a localized, wearable heat therapy that addresses meibomian gland dysfunction, a primary cause of evaporative dry eye. Its competitive advantages include ease of use, patient comfort, and clinical outcomes. Securing favorable reimbursement and driving patient and physician awareness are key to its competitive success in this segment.

Overall, Sight Sciences competes by investing in R&D to enhance existing products and develop new ones, generating robust clinical data, expanding sales and marketing efforts, and navigating the complex reimbursement landscape. Its ability to innovate and demonstrate superior patient outcomes is crucial for maintaining and expanding market share against both larger, more diversified companies and specialized competitors.

Risk Factors (Key Risks for Investors)

Investing in Sight Sciences involves several risks inherent to medical device companies, particularly those in growth phases:

• Reimbursement and Market Access: Securing and maintaining adequate reimbursement from government and private payers for both the OMNI and TearCare systems is critical. Changes in reimbursement policies or a failure to establish favorable coverage for new products could significantly impact revenue.
• Competition: The eye care market is highly competitive. Sight Sciences faces competition from established companies with greater resources and newer entrants. Its ability to differentiate products and maintain market share is vital.
• Financing and Liquidity: While currently well-capitalized, the company may require additional financing in the future to fund operations, R&D, or potential acquisitions. The availability and terms of such financing could impact its growth trajectory.
• Intellectual Property (IP): Protecting its patents and other intellectual property is crucial. The company faces risks of IP infringement by competitors or challenges to the validity of its patents, which could lead to costly litigation.
• Regulatory Environment: As a medical device company, Sight Sciences operates in a highly regulated environment. Changes in FDA regulations, compliance requirements, or product approval delays could adversely affect its business.
• Talent Acquisition and Retention: Attracting and retaining highly skilled employees, particularly in specialized fields like R&D, sales, and clinical affairs, is essential for continued innovation and growth.
• Stock Price Volatility: As a smaller, growth-oriented company, Sight Sciences' stock price can fluctuate significantly based on market sentiment, clinical trial results, regulatory news, and financial performance.
• Internal Controls: As an Emerging Growth Company, management has not yet assessed the effectiveness of its internal controls over financial reporting. While permissible under current regulations, investors should be aware of this factor.